Pembrolizumab,abiraterone,prednisone,olaparib,docetaxel,enzalutamide,dexamethasone,lenvatinib,vibostolimab,carboplatin,etoposide
Merck,eisai,janssen,astellas,pfizer
['abiraterone', 'crpc', 'prostate', 'abira', 'pembro']
2-year update sustains promise of pembrolizumab plus abiraterone in chemo-na ve mcrpc #urology #urologist #prostatecancer #esmo22
Expert clinical analysis. Practice advice. Policy perspectives.